Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 9/20 | 0.51 |
| ▸ | PPARA | Q07869 | 9/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477556 | 1.00 | CTSS (0.54) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL6476886 | 1.00 | CTSS (0.54) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL3619211 | 0.93 | PPARG (0.54) | CTSSCTSKPPARGPPARAPPARD | |
| SCHEMBL6480048 | 0.84 | CTSS (0.46) | CTSSCTSKPPARGPPARAHDAC4 | |
| SCHEMBL16945 | 0.82 | CTSK (0.70) | CTSSCTSKPPARGPPARAHDAC4 | |
| SCHEMBL9742302 | 0.82 | CTSK (0.70) | CTSSCTSKPPARGPPARAHDAC4 | |
| SCHEMBL21427213 | 0.82 | CTSK (0.70) | CTSSCTSKPPARGPPARAHDAC4 | |
| SCHEMBL21427220 | 0.82 | CTSK (0.70) | CTSSCTSKPPARGPPARAHDAC4 | |
| SCHEMBL8283416 | 0.82 | CTSK (0.70) | CTSSCTSKPPARGPPARAHDAC4 | |
| SCHEMBL9742291 | 0.82 | CTSK (0.70) | CTSSCTSKPPARGPPARAHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040030155-A1 | Process for preparing active esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | claimed |
| EP-1350790-A1 | PROCESS FOR PREPARING ACTIVE ESTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-08 | — | — | EP | claimed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7427634-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-23 | — | — | US | disclosed |
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-7166590-B2 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-20040030155-A1 | Process for preparing active esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | disclosed |
| EP-1350790-A1 | PROCESS FOR PREPARING ACTIVE ESTERS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-08 | — | — | EP | disclosed |
| US-6605608-B1 | Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors | ONO PHARMACEUTICAL CO., LTD (JP) | 2003-08-12 | — | — | US | disclosed |
| US-20030013725-A1 | Amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-01-16 | — | — | US | disclosed |
| EP-1097929-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-0997147-A1 | AMINO ACID DERIVATIVES | Ono Pharmaceutical Co., Ltd. (JP) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009890-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1B, CACNA1A | CTSS 601/4885CTSK 895/4885PPARG 2962/4885 |
| US-20040030155-A1 | Process for preparing active esters | CES1, CYP3A4, CYP3A5 | CTSS 711/4885CTSK 1139/4885PPARG 545/4885 |
| US-20030013725-A1 | Amino acid derivatives | CACNA1B, SCN1A, SCN2A | CTSS 1885/4885CTSK 3691/4885PPARG 4040/4885 |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1S, CACNA1B | CTSS 642/4885CTSK 1082/4885PPARG 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.